ES2472040R1 - Uso de paricalcitol en el tratamiento de la anemia inflamatoria - Google Patents

Uso de paricalcitol en el tratamiento de la anemia inflamatoria Download PDF

Info

Publication number
ES2472040R1
ES2472040R1 ES201430177A ES201430177A ES2472040R1 ES 2472040 R1 ES2472040 R1 ES 2472040R1 ES 201430177 A ES201430177 A ES 201430177A ES 201430177 A ES201430177 A ES 201430177A ES 2472040 R1 ES2472040 R1 ES 2472040R1
Authority
ES
Spain
Prior art keywords
paricalcitol
treatment
inflammatory anemia
stimulating agents
erythropoiesis stimulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201430177A
Other languages
English (en)
Other versions
ES2472040B1 (es
ES2472040A2 (es
Inventor
Miguel Giovanni URIOL RIVERA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to ES201430177A priority Critical patent/ES2472040B1/es
Publication of ES2472040A2 publication Critical patent/ES2472040A2/es
Publication of ES2472040R1 publication Critical patent/ES2472040R1/es
Priority to RU2016131412A priority patent/RU2016131412A/ru
Priority to MX2016010104A priority patent/MX365096B/es
Priority to EP15702156.9A priority patent/EP3104872B1/en
Priority to JP2016552329A priority patent/JP2017512753A/ja
Priority to US15/117,896 priority patent/US11464791B2/en
Priority to PT15702156T priority patent/PT3104872T/pt
Priority to ES15702156T priority patent/ES2728158T3/es
Priority to CN201580007824.4A priority patent/CN106061498B/zh
Priority to AU2015217956A priority patent/AU2015217956B2/en
Priority to DK15702156.9T priority patent/DK3104872T3/da
Priority to KR1020167023202A priority patent/KR20160113664A/ko
Priority to CA2938057A priority patent/CA2938057A1/en
Priority to PCT/EP2015/050817 priority patent/WO2015121022A1/en
Priority to UY35989A priority patent/UY35989A/es
Priority to ARP150100380A priority patent/AR099330A1/es
Application granted granted Critical
Publication of ES2472040B1 publication Critical patent/ES2472040B1/es
Priority to IL247207A priority patent/IL247207B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Uso de paricalcitol en el tratamiento de la anemia inflamatoria.#La presente invención describe el uso de paricalcitol, análogo sintético de la vitamina D, en el tratamiento de la anemia inflamatoria, preferentemente en combinación con agentes estimuladores de la eritropoyesis. El uso del paricalcitol para el tratamiento de dicha patología está asociado a un menor requerimiento de agentes estimuladores de la eritropoyesis, a una mejor utilización del hierro y a un incremento en los niveles de eritropoyetina plasmática, por parte de dichos pacientes. La presente invención describe además composiciones farmacéuticas que comprenden paricalcitol en combinación con agentes estimuladores de la eritropoyesis y excipientes farmacéuticamente aceptables, así como el uso de las mismas como medicamentos para el tratamiento de la anemia inflamatoria.
ES201430177A 2014-02-11 2014-02-11 Uso de paricalcitol en el tratamiento de la anemia inflamatoria Expired - Fee Related ES2472040B1 (es)

Priority Applications (17)

Application Number Priority Date Filing Date Title
ES201430177A ES2472040B1 (es) 2014-02-11 2014-02-11 Uso de paricalcitol en el tratamiento de la anemia inflamatoria
PCT/EP2015/050817 WO2015121022A1 (en) 2014-02-11 2015-01-16 Use of paricalcitol in the treatment of inflammatory anaemia
AU2015217956A AU2015217956B2 (en) 2014-02-11 2015-01-16 Use of paricalcitol in the treatment of inflammatory anaemia
DK15702156.9T DK3104872T3 (da) 2014-02-11 2015-01-16 Paricalcitol til anvendelse ved behandling af inflammatorisk
EP15702156.9A EP3104872B1 (en) 2014-02-11 2015-01-16 Paricalcitol for use in the treatment of inflammatory anaemia
JP2016552329A JP2017512753A (ja) 2014-02-11 2015-01-16 炎症性貧血の処置におけるパリカルシトールの使用
US15/117,896 US11464791B2 (en) 2014-02-11 2015-01-16 Use of paricalcitol in the treatment of inflammatory anaemia
PT15702156T PT3104872T (pt) 2014-02-11 2015-01-16 Paricalcitol para uso no tratamento de anemia inflamatória
ES15702156T ES2728158T3 (es) 2014-02-11 2015-01-16 Paricalcitol para uso en el tratamiento de la anemia inflamatoria
CN201580007824.4A CN106061498B (zh) 2014-02-11 2015-01-16 帕立骨化醇在炎性贫血的治疗中的用途
RU2016131412A RU2016131412A (ru) 2014-02-11 2015-01-16 Применение парикальцитола для лечения воспалительной анемии
MX2016010104A MX365096B (es) 2014-02-11 2015-01-16 Uso de paricalcitol en el tratamiento de la anemia inflamatoria.
KR1020167023202A KR20160113664A (ko) 2014-02-11 2015-01-16 염증성 빈혈 치료에 사용되는 파리칼시톨의 용도
CA2938057A CA2938057A1 (en) 2014-02-11 2015-01-16 Use of paricalcitol in the treatment of inflammatory anaemia
ARP150100380A AR099330A1 (es) 2014-02-11 2015-02-10 Uso de paricalcitol en el tratamiento de la anemia inflamatoria
UY35989A UY35989A (es) 2014-02-11 2015-02-10 Uso de paricalcitol en el tratamiento de la anemia inflamatoria
IL247207A IL247207B (en) 2014-02-11 2016-08-10 Use of pericalcitol in the treatment of inflammatory anemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201430177A ES2472040B1 (es) 2014-02-11 2014-02-11 Uso de paricalcitol en el tratamiento de la anemia inflamatoria

Publications (3)

Publication Number Publication Date
ES2472040A2 ES2472040A2 (es) 2014-06-27
ES2472040R1 true ES2472040R1 (es) 2014-09-18
ES2472040B1 ES2472040B1 (es) 2015-07-01

Family

ID=51205045

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201430177A Expired - Fee Related ES2472040B1 (es) 2014-02-11 2014-02-11 Uso de paricalcitol en el tratamiento de la anemia inflamatoria
ES15702156T Active ES2728158T3 (es) 2014-02-11 2015-01-16 Paricalcitol para uso en el tratamiento de la anemia inflamatoria

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15702156T Active ES2728158T3 (es) 2014-02-11 2015-01-16 Paricalcitol para uso en el tratamiento de la anemia inflamatoria

Country Status (16)

Country Link
US (1) US11464791B2 (es)
EP (1) EP3104872B1 (es)
JP (1) JP2017512753A (es)
KR (1) KR20160113664A (es)
CN (1) CN106061498B (es)
AR (1) AR099330A1 (es)
AU (1) AU2015217956B2 (es)
CA (1) CA2938057A1 (es)
DK (1) DK3104872T3 (es)
ES (2) ES2472040B1 (es)
IL (1) IL247207B (es)
MX (1) MX365096B (es)
PT (1) PT3104872T (es)
RU (1) RU2016131412A (es)
UY (1) UY35989A (es)
WO (1) WO2015121022A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102504090B1 (ko) * 2020-08-05 2023-02-24 경상국립대학교병원 조영제-유발 신독성 예방 또는 치료용 약학 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054620A1 (en) 2003-01-13 2005-03-10 Koeffler H. Phillip Paricalcitol as a chemotherapeutic agent
US20080194475A1 (en) * 2004-04-23 2008-08-14 Andrew Buchanan Erythropoietin Protein Variants
WO2008086025A2 (en) * 2007-01-10 2008-07-17 Edison Pharmaceuticals, Inc. Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
CN102772364B (zh) * 2011-05-13 2015-12-02 重庆华邦制药有限公司 帕立骨化醇的脂肪乳及其制剂和制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAPUANO ALFREDO et al. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.JN Journal of Nephrology JAN-FEB 2009 00/01/2009 VOL: 22 No: 1 Pags: 59-68 ISSN 1121-8428, todo el documento. *
ICARDI A et al. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: The potential role of inflammation.Nephrology Dialysis Transplantation 2013 Oxford University Press gbr 00/07/2013 VOL: 28 No: 7 Pags: 1672 - 1679 ISSN 0931-0509 (print) ISSN 1460-2385 (electronic) Doi: doi:10.1093/ndt/gft021, todo el documento. *
SHUJA SUHAIL B et al. Severe hyperparathyroidism despite paricalcitol therapy: one-year follow-up..Advances in peritoneal dialysis. Conference on Peritoneal Dialysis Canada 2003 00/00/2003 VOL: 19 Pags: 231 - 235 ISSN 1197-8554 (Print) Doi: pubmed:14763069, todo el documento. *

Also Published As

Publication number Publication date
KR20160113664A (ko) 2016-09-30
AR099330A1 (es) 2016-07-13
MX365096B (es) 2019-05-22
AU2015217956B2 (en) 2019-04-04
US20160367571A1 (en) 2016-12-22
CA2938057A1 (en) 2015-08-20
JP2017512753A (ja) 2017-05-25
ES2728158T3 (es) 2019-10-22
AU2015217956A1 (en) 2016-08-25
RU2016131412A (ru) 2018-03-15
UY35989A (es) 2015-03-27
EP3104872A1 (en) 2016-12-21
WO2015121022A1 (en) 2015-08-20
PT3104872T (pt) 2019-06-11
DK3104872T3 (da) 2019-06-17
ES2472040B1 (es) 2015-07-01
EP3104872B1 (en) 2019-03-13
IL247207A0 (en) 2016-09-29
ES2472040A2 (es) 2014-06-27
US11464791B2 (en) 2022-10-11
IL247207B (en) 2020-02-27
CN106061498A (zh) 2016-10-26
CN106061498B (zh) 2019-12-06
MX2016010104A (es) 2017-01-06

Similar Documents

Publication Publication Date Title
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
UY35916A (es) Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
BR112016020618A8 (pt) oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido
BR112016025997A2 (pt) compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica
CR20160485A (es) Compuesto de ciclopropanamina y sus usos
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CR20180228A (es) Terapia adjunta con 25-hidroxi vitamina d y articulos de la misma
CO2017002472A2 (es) Formulación de acetato de abiraterona
PH12016501841A1 (en) Immunosuppressant formulation
CL2015001610A1 (es) Compuestos derivados de pirimido-[4,5-b]-quinolina-4,5(3h,10h)-dionas para utilizarse como un medicamento para el tratamiento de una enfermedad causada por una mutacion sin sentido; composicion y combinacion farmaceutica que los comprende.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
UY36677A (es) Compuestos tricíclicos como agentes antineoplásicos
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
BR112017028468A2 (pt) formulação sólida oral, e método para preparar uma formulação sólida oral
CO2019004131A2 (es) Glicinato de metformina, composiciones farmacéuticas que comprenden la misma, y métodos de uso de la misma
CL2016000884A1 (es) Derivados de piperazina y su uso como medicamento.
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
IT201600081379A1 (it) Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.
IT201600103956A1 (it) Formulazione oftalmica comprendente citicolina veicolata da liposomi per il trattamento del glaucoma
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
CO2018008626A2 (es) Formulaciones de oritavancina
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2472040

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150701

FD2A Announcement of lapse in spain

Effective date: 20211004